United States Policy Implications of Generic Substitution of Branded Human Immunodeficiency Virus Medications

Andrew P. Brogan; Susan L. Hogue; Susan L. Hogue; Andrew P. Brogan; B Goodwin

United States Policy Implications of Generic Substitution of Branded Human Immunodeficiency Virus Medications

Hogue, S., Brogan, A., & Goodwin, B. (2013). United States Policy Implications of Generic Substitution of Branded Human Immunodeficiency Virus Medications. Value in Health, 16(7), A364-A365.

Copy citation

Recent Publications

Article

Treatment preferences among patients with mild-to-moderate atopic dermatitis

December 31, 2023

Article

Understanding how infection prevention influences nurses' task sequencing using a mixed-methods, simulation-based approach

December 01, 2023

Article

Consensus-based framework for evaluating data modernization initiatives

October 01, 2023

Article

∆8-THC-COOH cross-reactivity with cannabinoid immunoassay kits and interference in chromatographic testing methods

September 15, 2023

View All Publications